JP2017514801A5 - - Google Patents

Download PDF

Info

Publication number
JP2017514801A5
JP2017514801A5 JP2016561311A JP2016561311A JP2017514801A5 JP 2017514801 A5 JP2017514801 A5 JP 2017514801A5 JP 2016561311 A JP2016561311 A JP 2016561311A JP 2016561311 A JP2016561311 A JP 2016561311A JP 2017514801 A5 JP2017514801 A5 JP 2017514801A5
Authority
JP
Japan
Prior art keywords
xaa
chem
glu
lys
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016561311A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514801A (ja
JP6768515B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/057442 external-priority patent/WO2015155151A1/en
Publication of JP2017514801A publication Critical patent/JP2017514801A/ja
Publication of JP2017514801A5 publication Critical patent/JP2017514801A5/ja
Application granted granted Critical
Publication of JP6768515B2 publication Critical patent/JP6768515B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016561311A 2014-04-07 2015-04-07 二重アシル化glp−1化合物 Active JP6768515B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14163697 2014-04-07
EP14163697.7 2014-04-07
PCT/EP2015/057442 WO2015155151A1 (en) 2014-04-07 2015-04-07 Double-acylated glp-1 compounds

Publications (3)

Publication Number Publication Date
JP2017514801A JP2017514801A (ja) 2017-06-08
JP2017514801A5 true JP2017514801A5 (enExample) 2018-05-10
JP6768515B2 JP6768515B2 (ja) 2020-10-14

Family

ID=50434120

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016561311A Active JP6768515B2 (ja) 2014-04-07 2015-04-07 二重アシル化glp−1化合物

Country Status (6)

Country Link
US (1) US10689429B2 (enExample)
EP (1) EP3129041B1 (enExample)
JP (1) JP6768515B2 (enExample)
CN (1) CN106132985B (enExample)
ES (1) ES2741507T3 (enExample)
WO (1) WO2015155151A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
CN108699126B (zh) 2016-03-03 2022-12-06 诺和诺德股份有限公司 Glp-1衍生物及其用途
AR112015A1 (es) 2017-06-09 2019-09-11 Novo Nordisk As Composiciones sólidas para administración oral
HUE066356T2 (hu) 2017-08-24 2024-07-28 Novo Nordisk As GLP-1 készítmények és alkalmazásaik
WO2019149880A1 (en) * 2018-02-02 2019-08-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
WO2019200594A1 (zh) * 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 酰化的glp-1衍生物
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
KR102911883B1 (ko) 2018-10-11 2026-01-13 인타르시아 세라퓨틱스 인코포레이티드 인간 아밀린 유사체 폴리펩타이드 및 사용 방법
CN111378027B (zh) * 2018-12-29 2022-04-15 万新医药科技(苏州)有限公司 一种索玛鲁肽前体的制备方法
CN114340655A (zh) * 2019-09-02 2022-04-12 诺和诺德股份有限公司 生产包含glp-1肽的片剂的方法
HRP20241052T1 (hr) 2019-11-06 2024-11-08 Novo Nordisk A/S Semaglutid, namijenjen liječenju alzheimerove demencije
CN114641276A (zh) 2019-11-07 2022-06-17 诺和诺德股份有限公司 包含glp-1激动剂、sglt2抑制剂和n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐的固体组合物
PE20221575A1 (es) 2020-02-18 2022-10-06 Novo Nordisk As Formulaciones farmaceuticas
US20230165939A1 (en) 2020-04-29 2023-06-01 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and histidine
CN116438456A (zh) 2020-09-11 2023-07-14 格里姆普斯生物股份有限公司 用于疾病检测/诊断、分期、监测和治疗的离体蛋白酶活性检测
EP4222176A4 (en) 2020-09-30 2024-02-28 Beijing QL Biopharmaceutical Co., Ltd. POLYPEPTIDE CONJUGATES AND METHODS OF USE
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
KR20240163717A (ko) 2022-03-30 2024-11-19 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 폴리펩티드 접합체의 액체 약학 조성물 및 그의 사용 방법
CA3266547A1 (en) 2022-08-29 2024-03-07 Eli Lilly And Company COMPOSITIONS FOR ORAL ADMINISTRATION
TW202421645A (zh) 2022-11-25 2024-06-01 丹麥商諾佛 儂迪克股份有限公司 如glp—1之肽治療劑的口服投與
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3149958B2 (ja) * 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Glp―1誘導体
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
WO1999043706A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Derivatives of glp-1 analogs
WO2000034331A2 (en) 1998-12-07 2000-06-15 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Analogues of glp-1
AU1269501A (en) 1999-11-12 2001-05-30 Novo Nordisk A/S Use of glp-1 agonists for the inhibition of beta cell degeneration
US6693094B2 (en) * 2001-03-22 2004-02-17 Chrono Rx Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
KR20050049525A (ko) * 2002-10-11 2005-05-25 가부시키가이샤산와카가쿠켄큐쇼 Glp-1 유도체 및 그의 경점막 흡수형 제제
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
CA2784757A1 (en) * 2009-12-16 2011-07-07 Novo Nordisk A/S Double-acylated glp-1 derivatives
US9708383B2 (en) 2010-11-09 2017-07-18 Novo Nordisk A/S Double-acylated GLP-1 derivatives
JP2014502985A (ja) * 2011-01-19 2014-02-06 ノヴォ ノルディスク アー/エス Glp−1粒子および組成物
DK2696687T3 (en) * 2011-04-12 2017-02-06 Novo Nordisk As Double-acylated GLP-1 derivatives
CN107266558A (zh) 2011-09-06 2017-10-20 诺沃—诺迪斯克有限公司 Glp‑1衍生物
CN104411322B (zh) * 2012-05-08 2017-05-24 诺和诺德股份有限公司 双酰化glp‑1衍生物
EP2846823B1 (en) * 2012-05-08 2019-12-04 Novo Nordisk A/S Double-acylated glp-1 derivatives
CA2899220A1 (en) * 2013-01-29 2014-08-07 Oshadi Drug Administration Ltd. Pharmaceutical compositions for oral treatment of diabetes

Similar Documents

Publication Publication Date Title
JP2014529629A5 (enExample)
JP2013543853A5 (enExample)
JP2014501712A5 (enExample)
JP2015517478A5 (enExample)
JP2015517477A5 (enExample)
JP2010538049A5 (enExample)
MX355361B (es) Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados.
CN103200966B (zh) 具有接头的双-酰化的glp-1衍生物
JP2016526012A5 (enExample)
JP4585037B2 (ja) アシル化glp−1化合物
JP2013517307A5 (enExample)
JP2008533105A5 (enExample)
JP2022509568A5 (enExample)
JP7432361B2 (ja) ヒトインスリンまたはそのアナログのアシル化誘導体
JP2023510206A (ja) インスリン誘導体
JP2012529463A5 (enExample)
JP2011511753A5 (enExample)
JP2010529004A5 (enExample)
WO2019110773A1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
RU2012128547A (ru) Дважды ацилированные производные glp-1
JP2012506402A5 (enExample)
JP2005528337A5 (enExample)
JP2007537142A (ja) アルブミン様物質に結合した新規のglp−1類似物
WO2015013169A9 (en) Bioconjugates of synthetic apelin polypeptides
NZ597554A (en) Selective glucagon-like-peptide-2 (glp-2) analogues